at siga, we specialize in developing therapeutic solutions for some of the most lethal pathogens – smallpox, ebola, dengue, lassa fever and other dangerous viruses. our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats.
Company profile
Ticker
SIGA
Exchange
Website
CEO
Phillip Louis Gomez III
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SIGA PHARMACEUTICALS INC
SEC CIK
Corporate docs
IRS number
133864870
SIGA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Entry into a Material Definitive Agreement
1 Apr 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
SIGA Reports Financial Results for Three and Twelve
12 Mar 24
8-K
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer
22 Jan 24
8-K
Departure of Directors or Certain Officers
2 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Results of Operations and Financial Condition
7 Nov 23
Transcripts
SIGA
Earnings call transcript
2023 Q4
12 Mar 24
SIGA
Earnings call transcript
2023 Q3
7 Nov 23
SIGA
Earnings call transcript
2023 Q2
8 Aug 23
SIGA
Earnings call transcript
2023 Q1
4 May 23
SIGA
Earnings call transcript
2022 Q4
2 Mar 23
SIGA
Earnings call transcript
2022 Q3
3 Nov 22
SIGA
Earnings call transcript
2022 Q2
7 Aug 22
SIGA
Earnings call transcript
2022 Q1
8 May 22
SIGA
Earnings call transcript
2021 Q4
4 Mar 22
SIGA
Earnings call transcript
2021 Q3
7 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 71.11 mm | 71.11 mm | 71.11 mm | 71.11 mm | 71.11 mm | 71.11 mm |
Cash burn (monthly) | 1.70 mm | 3.22 mm | 436.41 k | 821.72 k | 1.70 mm | (no burn) |
Cash used (since last report) | 11.73 mm | 22.22 mm | 3.01 mm | 5.67 mm | 11.73 mm | n/a |
Cash remaining | 59.38 mm | 48.90 mm | 68.10 mm | 65.44 mm | 59.38 mm | n/a |
Runway (months of cash) | 34.9 | 15.2 | 156.0 | 79.6 | 34.9 | n/a |
Institutional ownership, Q3 2023
53.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 130 |
Opened positions | 21 |
Closed positions | 23 |
Increased positions | 42 |
Reduced positions | 40 |
13F shares | Current |
---|---|
Total value | 177.38 bn |
Total shares | 38.22 mm |
Total puts | 283.90 k |
Total calls | 297.50 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
FHI Federated Hermes Inc - Ordinary Shares | 4.36 mm | $22.91 bn |
BLK Blackrock | 3.36 mm | $17.66 bn |
Esopus Creek Value Series Fund LP - Series A | 2.37 mm | $21.94 mm |
GS Goldman Sachs | 2.31 mm | $12.11 bn |
Vanguard | 2.20 mm | $11.57 bn |
AltraVue Capital | 2.11 mm | $11.06 bn |
First Wilshire Securities Management | 2.07 mm | $10.82 bn |
Kempen Capital Management | 1.93 mm | $10.14 bn |
D. E. Shaw & Co | 1.49 mm | $0.00 |
Dimensional Fund Advisors | 1.47 mm | $7.73 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Larry R. Miller | Common Stock, par value $.0001 per share | Payment of exercise | Dispose F | No | No | 8.35 | 19,040 | 158.98 k | 30,900 |
25 Mar 24 | Larry R. Miller | Common Stock, par value $.0001 per share | Grant | Acquire A | No | No | 0 | 49,940 | 0.00 | 49,940 |
25 Mar 24 | Larry R. Miller | Performance Stock Units Common Stock, par value $.0001 per share | Grant | Acquire A | No | No | 0 | 20,761 | 0.00 | 20,761 |
25 Mar 24 | Larry R. Miller | RSU Common Stock, par value $.0001 per share | Grant | Acquire A | No | No | 0 | 20,761 | 0.00 | 20,761 |
25 Mar 24 | Larry R. Miller | Stock Option Common Stock, par value $.0001 per share | Grant | Acquire A | No | No | 8.35 | 25,504 | 212.96 k | 25,504 |
25 Mar 24 | Larry R. Miller | Stock Option Common Stock, par value $.0001 per share | Grant | Acquire A | No | No | 8.35 | 61,347 | 512.25 k | 61,347 |
27 Jan 24 | Diem Nguyen | Performance Stock Units Common Stock, par value $.0001 per share | Grant | Acquire A | No | No | 0 | 177,865 | 0.00 | 177,865 |
27 Jan 24 | Diem Nguyen | RSU Common Stock, par value $.0001 per share | Grant | Acquire A | No | No | 0 | 167,707 | 0.00 | 167,707 |
27 Jan 24 | Diem Nguyen | Stock Option Common Stock, par value $.0001 per share | Grant | Acquire A | No | No | 5.06 | 219,212 | 1.11 mm | 219,212 |
27 Jan 24 | Diem Nguyen | Stock Option Common Stock, par value $.0001 per share | Grant | Acquire A | No | No | 5.06 | 109,606 | 554.61 k | 109,606 |
News
Watching SIGA Technologies; Traders Circulate The U.S. Sun Article Saying "A Mutant Strain Of Mpox With "New Pandemic Potential" Has Been Discovered In A Small Town In The Democratic Republic Of Congo, According To Research."
17 Apr 24
WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."
11 Apr 24
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
2 Apr 24
ChampionX, Montrose Environmental Group And Other Big Stocks Moving Higher On Tuesday
2 Apr 24
SIGA Technologies Enters Amendment To Its International Promotion Agreement With Meridian Medical
1 Apr 24
Press releases
SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®
1 Apr 24
SIGA Names Larry Miller General Counsel
25 Mar 24
Thinking about buying stock in Healthequity, Pacira Biosciences, Interpublic Group of Companies, SIGA Technologies, or Sensus Healthcare?
21 Mar 24
SIGA Declares Special Cash Dividend of $0.60 Per Share
12 Mar 24
SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results
5 Mar 24